Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
2005

EGFR Overexpression in Metaplastic Breast Carcinomas

Sample size: 25 publication Evidence: moderate

Author Information

Author(s): Jorge S Reis-Filho, Fernanda Milanezi, Silvia Carvalho, Pete T Simpson, Dawn Steele, Kay Savage, Maryou Lambros, Emilio M Pereira, Jahn M Nesland, Sunil R Lakhani, Fernando C Schmitt

Primary Institution: The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK

Hypothesis

Do metaplastic breast carcinomas exhibit HER2 and EGFR overexpression and gene amplification?

Conclusion

Metaplastic breast carcinomas frequently overexpress EGFR, which is associated with EGFR gene amplification in one-third of cases.

Supporting Evidence

  • 76% of metaplastic breast carcinomas exhibited EGFR overexpression.
  • 37% of cases with EGFR overexpression showed gene amplification.
  • No HER2 gene amplification was detected in the studied cases.

Takeaway

This study found that many metaplastic breast cancers have a lot of a protein called EGFR, which might help doctors find new treatments for these cancers.

Methodology

Twenty-five metaplastic breast carcinomas were analyzed using immunohistochemistry and chromogenic in situ hybridization for EGFR and HER2.

Limitations

The study had a small sample size and limited follow-up data.

Statistical Information

P-Value

p<0.001

Confidence Interval

95%

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/bcr1341

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication